SCHEMBL6325686

SCHEMBL6325686

[c]1cccc(-c2cccnc2)c1CNCC1CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.41
PDE5A O76074 2/20 0.40
VCP P55072 2/20 0.40
ADRA2C P18825 1/20 0.39
CYP2A6 P11509 2/20 0.38
CXCR4 P61073 1/20 0.38
HPGDS O60760 1/20 0.37
KDM1A O60341 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
KCNA5 P22460 2/20 0.36
IDO1 P14902 1/20 0.36
GBA1 P04062 1/20 0.36
CYP2E1 P05181 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2B6 P20813 1/20 0.36
CYP2C19 P33261 1/20 0.36
KDM4C Q9H3R0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320544 0.88 CYP2D6 (0.35) PIM1IDO1CYP2D6CYP2C9CYP2C19
SCHEMBL6640607 0.85 MEN1 (0.42) CXCR4IDO1CYP2D6CYP2C9CYP2C19
SCHEMBL6322030 0.81 ALDH1A1 (0.52) PIM1ADRA2CIDO1GBA1CYP2D6
SCHEMBL6329476 0.81 ALDH1A1 (0.49) PIM1ADRA2CHPGDSKCNA5IDO1
SCHEMBL6322319 0.80 MEN1 (0.37) PDE5ACXCR4CYP2D6CYP2C9CYP2C19
SCHEMBL6321221 0.77 GPR39 (0.42) CYP2D6CYP2C9CYP2C19
SCHEMBL7387127 0.73 HPGDS (0.41) ADRA2CCYP2A6HPGDSKCNA5CYP2E1
SCHEMBL8195408 0.72 CYP2A6 (0.41) ADRA2CCYP2A6KCNA5CYP2E1CYP2D6
SCHEMBL6331673 0.71 CYP2A6 (0.48) ADRA2CCYP2A6KCNA5CYP2E1CYP2D6
SCHEMBL12200976 0.71 CYP1A2 (0.67) CXCR4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951872-B2 Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-10-04 US disclosed
US-6858616-B2 Nitrogen containing heterobicycles as factor Xa inhibitors BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-02-22 US disclosed
EP-1140871-A4 THROMBIN OR FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB PHARMA CO (US) 2004-05-06 EP disclosed
US-6710058-B2 USE AS ANTICOAGULANT AGENTS FOR THERAPY AND PROPHYLAXIS OFTHROMBOEMBOLIC DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-23 US disclosed
US-6500855-B1 NITROGEN CONTAINING AROMATIC HETEROCYCLES WITH ORTHO-SUBSTITUTED P1 GROUPS; ANTICOAGULANTS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-12-31 US disclosed
US-6413980-B1 INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES; ANTICOAGULANTS; THROMBOEMBOLIC DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-07-02 US disclosed
US-6369227-B1 BLOOD COAGULATION BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-04-09 US disclosed
EP-1140941-A1 NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 2001-10-10 EP disclosed
EP-1140871-A1 THROMBIN OR FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 2001-10-10 EP disclosed
WO-2000039108-A1 THROMBIN OR FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 2000-07-06 WO disclosed
WO-2000039131-A1 NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 2000-07-06 WO disclosed